本文選題：易普利姆瑪　切入點(diǎn)：晚期黑色素瘤　出處：《中國新藥雜志》2017年08期 　論文類型：期刊論文

【摘要】：目的:系統(tǒng)評(píng)價(jià)易普利姆瑪?shù)挠行院桶踩�。方�?計(jì)算機(jī)檢索PubMed,Cochrane Library,Embase,中國知網(wǎng)、萬方和維普數(shù)據(jù)庫。由2位研究者按照納入和排除標(biāo)準(zhǔn)篩選文獻(xiàn)、提取資料和質(zhì)量評(píng)價(jià)后,采用RevMan 5.3軟件進(jìn)行Meta分析。結(jié)果:納入4項(xiàng)隨機(jī)對(duì)照試驗(yàn),共2 622例病例。Meta分析結(jié)果顯示:與對(duì)照組相比,易普利姆瑪組1年無進(jìn)展生存率(RR=0.94,95%CI:0.91~0.98,P=0.001)、1年總生存率(RR=0.79,95%CI:0.72~0.87,P0.000 01)較高,具有統(tǒng)計(jì)學(xué)差異。2年無進(jìn)展生存率無統(tǒng)計(jì)學(xué)差異(RR=0.99,95%CI:0.97~1.01,P=0.45)及3年總生存率(RR=0.93,95%CI:0.84~1.03,P=0.17)均無統(tǒng)計(jì)學(xué)差異。易普利姆瑪組患者皮疹(RR=2.43,95%CI:1.64~3.61,P0.000 01)、瘙癢(RR=2.35,95%CI:1.67~3.29,P0.000 01)、腹瀉(RR=1.82,95%CI:1.47~2.25,P0.000 01)、結(jié)腸炎(RR=11.21,95%CI:6.20~20.30,P0.000 01)、丙氨酸氨基轉(zhuǎn)移酶增高(RR=3.57,95%CI:1.92~6.62,P0.000 1)、天門冬氨酸氨基轉(zhuǎn)移酶增高(RR=3.81,95%CI:2.85~5.09,P0.000 01)的發(fā)生率均較高。結(jié)論:與對(duì)照組相比,易普利姆瑪可提高患者1年無進(jìn)展生存率、1年總生存率,但在2年無進(jìn)展生存率及3年總生存率未顯示出優(yōu)勢,且易普利姆瑪增加了患者出現(xiàn)皮疹、瘙癢、腹瀉、結(jié)腸炎和轉(zhuǎn)氨酶升高的風(fēng)險(xiǎn)。
[Abstract]:Objective: to systematically evaluate the efficacy and safety of Eprimma. Methods: a computer-based search of the PubMedCochrane Library Embase, China knowledge Network, Wanfang and Weipu databases was conducted. The literature was selected by two researchers according to the inclusion and exclusion criteria, and the data were extracted and the quality evaluated. Results: a total of 2 622 cases were enrolled in 4 randomized controlled trials. Meta-analysis results showed that compared with the control group, the 1 year progression free survival rate of the Iprimma group was higher than that of the control group, and the 1 year overall survival rate was higher than that of the control group, and the 1 year overall survival rate was higher than that of the control group. There was no statistical difference in the 2-year progression-free survival rate. There was no statistical difference in the 2-year progression-free survival rate (RRR0.9395CI0.971P0.45) and the overall 3-year survival rate (RR0.9395CI0.841.0395 CI0.841.03P0.17). There was no statistical difference in the 2-year progression-free survival rate. No statistical difference was found in the 2-year progressive survival rate. No statistical difference was found in the 2-year progression-free survival rate. There was no statistical difference in the 2-year progressive survival rate. There was no statistical difference in the 2-year progression-free survival rate. There was no statistical difference in the 2-year progression-free survival rate. There was no statistical difference in the 2-year progression-free survival rate. There was no statistical difference in the 2-year progression-free survival rate. There was no statistical difference in the 2-year progression-free survival rate. No statistical difference was found in the 2-year progression survival rate. There was no statistical difference in the 2-year progression survival rate. There was no statistical difference in the 2-year progression survival rate. There was no statistical difference in the 2-year progress-free survival rate. The incidence of RRN 3.5795% CIW 1.92C6.62KP0.000 and aspartate aminotransferase RRN 3.8195% is higher than that of the control group. Conclusion: compared with the control group, the incidence of RRN is higher than that of the control group. The 1-year progression-free survival rate and 1-year overall survival rate were improved by Iprimma, but the 2-year progression-free survival rate and 3-year overall survival rate did not show any advantage, and Iprimma increased the incidence of rash, pruritus and diarrhea. Increased risk of colitis and transaminase.
【作者單位】： 重慶醫(yī)科大學(xué)附屬第一醫(yī)院皮膚科;
【分類號(hào)】：R739.5

【相似文獻(xiàn)】

相關(guān)碩士學(xué)位論文 前1條

1 肖建東;羅格列酮、咪達(dá)普利單用和聯(lián)合治療癌癥惡病質(zhì)的實(shí)驗(yàn)性研究[D];福建醫(yī)科大學(xué);2012年

，

本文編號(hào)：1590452